Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide sodium, quantity: 10.664 mg/ml (equivalent: furosemide, qty 10 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication, or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

takeda new zealand limited - teduglutide 5mg; water for injection 0.5 ml - powder for injection with diluent - 5 mg - active: teduglutide 5mg excipient: dibasic sodium phosphate heptahydrate histidine hydrochloric acid mannitol monobasic sodium phosphate monohydrate sodium hydroxide water for injection active: water for injection 0.5 ml - revestive is indicated for the treatment of adult patients with short bowel syndrome (sbs) who are dependent on parenteral support. patients should be stable at least to 4 weeks on their parenteral support regimen before initiating teduglutide therapy

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; mannitol; sodium hydroxide - frusemide high dosage formulations are intended exclusively for patients with severely impaired renal function. use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function, e.g. in chronic glomerular nephritis, lupus erythematosus and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day, dialysis has to be used.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide sodium, quantity: 10.664 mg/ml (equivalent: furosemide, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.

Israel - Inggeris - Ministry of Health

amgen europe b.v. - romosozumab - solution for injection - romosozumab 90 mg / 1 ml - romosozumab - evenity is indicated for the treatment of severe osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - furosemide - solution for injection - 10mg/1ml

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - frusemide - solution for injection/infusion - 20 mg/2ml - sulfonamides, plain; furosemide

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - articaine hydrochloride, quantity: 88 mg; adrenaline (epinephrine) acid tartrate, quantity: 0.02 mg (equivalent: adrenaline (epinephrine), qty 0.011 mg) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; sodium hydroxide; water for injections - ? septanest 1:200,000 is indicated for local anaesthesia for simple dental procedures in adults, adolescents and children 4 years of age and older. ? septanest 1:200,000 is indicated only for dental procedures

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - articaine hydrochloride, quantity: 68 mg; adrenaline (epinephrine) acid tartrate, quantity: 0.0155 mg (equivalent: adrenaline (epinephrine), qty 0.0085 mg) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; sodium hydroxide; water for injections - ? septanest 1:200,000 is indicated for local anaesthesia for simple dental procedures in adults, adolescents and children 4 years of age and older. ? septanest 1:200,000 is indicated only for dental procedures